To conclude, clinical presentation of the tumor, proven HER2-positivity, absence of TP53 mutation, genomic profile without characteristic pattern of BRCA1 inactivated tumors (no genomic BRCAness) and loss of the mutated BRCA1 allele in tumor evidence that the case represented a HER2-positive breast cancer without BRCA1 inactivation. Here, ERBB2 is linked to neoplasm.